Biography:Ramakanth Sarabu

From HandWiki
Short description: Indian chemist (1955–2021)
Ramakanth Sarabu
Ramakanth Sarabu.jpg
Image of Ramakanth Sarabu
Born
Ramakanth Sarabu

(1955-06-20)June 20, 1955
Telangana, India
DiedFebruary 11, 2021(2021-02-11) (aged 65)
NationalityIndia n
CitizenshipAmerican
Alma materOsmania University * Indian Institute of Technology * Case Western Reserve University * Harvard University
Scientific career
FieldsMedicinal Chemistry
Organic Chemistry
Drug Discovery
Diabetes Research
InstitutionsHoffmann-La Roche
Biocon Bristol Myers Squib
Cellarity

Ramakanth Sarabu (June 20, 1955 – February 11, 2021) was an Indian organic chemist. He is known for his contributions in diabetes research, specifically the work of Glucokinase activation as a treatment therapy for type 2 diabetes.

Biography

Ramakanth Sarabu was born in Hyderabad, Telangana where he received his early education. He earned a master's degree from Osmania University in Organic Chemistry and his doctorate from Indian Institute of Technology, Madras in Molecular Rearrangements from 1979 to 1984.[1] In 1984 he moved to the US to pursue post-doctoral fellowship under Elias James Corey, at Harvard University.[2][3][4] He did a second post-doctoral fellowship in 1985 at Case Western University in Cleveland, OH.[5][6] He is known for his works and contributions in the domain of Glucokinase activation as a treatment therapy for type 2 diabetes.[7]

He died on 11 February 2021 in Montville, New Jersey,[8] while serving as the Head of Chemistry at Cellarity.[9][10] Prior to that, from 1997 to 2012, he served at Hoffmann-La Roche at different positions like Research Leader, Senior Principal Scientist etc.[11] He then went on to become the Head of Medicinal Chemistry at Biocon Bristol Myers Squibb R&D Center from 2012 to 2019.[12][13][14][15]

Notable publications

  • Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes—a status review. Current Opinion in Drug Discovery & Development. 2005 Sep;8(5):631–637.
  • Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy, Science Magazine 18 June 2003.[16]
  • Philip Garner and Sarabu Ramakanth, Stereodivergent synthesis of threo and erythro 6-amino-6-deoxyheptosulose derivatives via an optically active oxazolidine aldehyde, https://doi.org/10.1021/jo00363a044
  • Philip Garner and Sarabu Ramakanth, A regiocontrolled synthesis of N7- and N9-guanine nucleosides https://doi.org/10.1021/jo00241a032
  • David R. Bolin, Amy L. Swain, Ramakanth Sarabu, Steven J. Berthel etc. Peptide and Peptide Mimetic Inhibitors of Antigen Presentation by HLA-DR Class II MHC Molecules. Design, Structure−Activity Relationships, and X-ray Crystal Structures https://doi.org/10.1021/jm000034h
  • Glucokinase Activators for Diabetes Therapy – Franz M. Matschinsky, Bogumil Zelent, Nicolai Doliba, Changhong Li, Jane M. Vanderkooi, Ali Naji, Ramakanth Sarabu, Joseph Grimsby, Diabetes Care May 2011, 34 (Supplement 2) S236-S243; DOI: 10.2337/dc11-s236[17]
  • Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics- Nicolai M. Doliba, Wei Qin, Habiba Najafi, Chengyang Liu, Carol W. Buettger, Johanna Sotiris, Heather W. Collins, Changhong Li, Charles A. Stanley, David F. Wilson, Joseph Grimsby, Ramakanth Sarabu, Ali Naji, and Franz M. Matschinsky, American Journal of Physiology. Endocrinology and Metabolism 2012 302:1, E87-E102, https://doi.org/10.1152/ajpendo.00218.2011
  • Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients – Ramakanth Sarabu, Fred T. Bizzarro, Wendy L. Corbett etc. https://doi.org/10.1021/jm3008689
  • Glucokinase Activators for the Potential Treatment of Type 2 Diabetes, Grimsby, J.; Berthel, S. J.; Sarabu, R.Current Topics in Medicinal Chemistry, Volume 8, Number 17, 2008, pp. 1524–1532(9), https://doi.org/10.2174/156802608786413483

Notable Patents

  • Para-amine substituted phenylamide glucokinase activators[18]
  • α-acyl- and α-heteroatom-substituted benzene acetamide glucokinase activators[19]
  • 5-substituted-six-membered heteroaromatic glucokinase activators[20]
  • DPP IV inhibitors[21]

References

  1. ↑ ORCID. "Ramakanth Sarabu (0000-0001-6083-3045)" (in en). https://orcid.org/0000-0001-6083-3045. 
  2. ↑ Garner, Philip; Ramakanth, Sarabu (1986-06-01). "Stereodivergent synthesis of threo and erythro 6-amino-6-deoxyheptosulose derivatives via an optically active oxazolidine aldehyde". The Journal of Organic Chemistry 51 (13): 2609–2612. doi:10.1021/jo00363a044. ISSN 0022-3263. https://doi.org/10.1021/jo00363a044. 
  3. ↑ "Group Members: Elias James Corey". http://www.hcs.harvard.edu/coreylab/members/members.php. 
  4. ↑ "Photo Gallery: Elias James Corey". http://www.hcs.harvard.edu/coreylab/gallery/gallery.php. 
  5. ↑ "Ramakanth Sarabu, Head of Chemistry, Cellarity". https://www.topionetworks.com/people/ramakanth-sarabu-604cdaee843bac550b6aba37. 
  6. ↑ Park, Jung Min (1990). The development of a synthetically useful penaldic acid equivalent and its application to the asymmetric synthesis of polyoxin J (PhD dissertation). Case Western Reserve University.
  7. ↑ Grimsby, J.; Berthel, S. J.; Sarabu, R. (2008-11-01). "Glucokinase Activators for the Potential Treatment of Type 2 Diabetes". Current Topics in Medicinal Chemistry 8 (17): 1524–1532. doi:10.2174/156802608786413483. PMID 19075763. https://www.ingentaconnect.com/content/ben/ctmc/2008/00000008/00000017/art00004. 
  8. ↑ "Ramakanth Sarabu Obituary - Visitation & Funeral Information". https://shookscedargrove.com/book-of-memories/4531114/Sarabu-Dr-Ramakanth/index.php. 
  9. ↑ "Ramakanth Sarabu" (in en). https://cellarity.com/team/ramakanth-sarabu. 
  10. ↑ Line, A. TARDE On. "Cellarity se associa à Excelra para enriquecer o banco de dados GOSTAR com a plataforma de descoberta de medicamentos" (in pt-br). http://www.atarde.com.br/economia/pr-newswire/noticias/2145040-cellarity-se-associa-a-excelra-para-enriquecer-o-banco-de-dados-gostar-com-a-plataforma-de-descoberta-de-medicamentos. 
  11. ↑ "Ramakanth Sarabu, Head of Chemistry, Cellarity". https://www.topionetworks.com/people/ramakanth-sarabu-604cdaee843bac550b6aba37. 
  12. ↑ Bajpai, Lakshmikant; Asokan, Kathiravan; Samy, Santhiagu; Murugesan, Shyamsundar; Gurram, Ramya; Lokamma, Leelavathi; Kanthappa, Venkatesh T.; Zhang, Yingru (2016-12-01). "A Simple and Efficient Approach for Estimating Recovery of a Preparative Reversed Phase HPLC Purification" (in en). Chromatographia 79 (23): 1577–1583. doi:10.1007/s10337-016-3191-0. ISSN 1612-1112. https://doi.org/10.1007/s10337-016-3191-0. 
  13. ↑ "Europe PMC". https://europepmc.org/search?query=AUTH:%22Ramakanth%20Sarabu%22. 
  14. ↑ Subbaiah, Murugaiah A. M.; Meanwell, Nicholas A.; Kadow, John F.; Subramani, Lakshumanan; Annadurai, Mathiazhagan; Ramar, Thangeswaran; Desai, Salil D.; Sinha, Sarmistha et al. (2018-05-10). "Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir". Journal of Medicinal Chemistry 61 (9): 4176–4188. doi:10.1021/acs.jmedchem.8b00277. ISSN 0022-2623. PMID 29693401. https://doi.org/10.1021/acs.jmedchem.8b00277. 
  15. ↑ Tiwari, Ranjeet; Ahire, Deepak; Kumar, Hemantha; Sinha, Sarmistha; Chauthe, Siddheshwar Kisan; Subramanian, Murali; Iyer, Ramaswamy; Sarabu, Ramakanth et al. (2017-12-01). "Use of Hybrid Capillary Tube Apparatus on 400 MHz NMR for Quantitation of Crucial Low-Quantity Metabolites Using aSICCO Signal" (in en). Drug Metabolism and Disposition 45 (12): 1215–1224. doi:10.1124/dmd.117.077073. ISSN 0090-9556. PMID 28935657. https://dmd.aspetjournals.org/content/45/12/1215. 
  16. ↑ Grimsby, Joseph; Sarabu, Ramakanth; Corbett, Wendy L.; Haynes, Nancy-Ellen; Bizzarro, Fred T.; Coffey, John W.; Guertin, Kevin R.; Hilliard, Darryl W. et al. (2003-07-18). "Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy" (in en). Science 301 (5631): 370–373. doi:10.1126/science.1084073. ISSN 0036-8075. PMID 12869762. https://www.science.org/doi/10.1126/science.1084073. 
  17. ↑ Matschinsky, Franz M.; Zelent, Bogumil; Doliba, Nicolai; Li, Changhong; Vanderkooi, Jane M.; Naji, Ali; Sarabu, Ramakanth; Grimsby, Joseph (2011-05-01). "Glucokinase Activators for Diabetes Therapy: May 2010 status report" (in en). Diabetes Care 34 (Supplement 2): S236–S243. doi:10.2337/dc11-s236. ISSN 0149-5992. PMID 21525462. PMC 3632186. https://care.diabetesjournals.org/content/34/Supplement_2/S236. 
  18. ↑ Bizzarro, Fred; Nancy-Ellen Haynes & Ramakanth Sarabu, "Para-amine substituted phenylamide glucokinase activators", US patent 6489485, published 2002-12-03
  19. ↑ Kester, Robert Francis & Ramakanth Sarabu, "α-acyl- and α-heteroatom-substituted benzene acetamide glucokinase activators", US patent 6608218, published 2003-08-19
  20. ↑ Chen, Shaoqing; Wendy Lea Corbett & Kevin Richard Guertin et al., "5-substituted-six-membered heteroaromatic glucokinase activators", US patent 7132425, published 2006-11-07
  21. ↑ Boehringer, Markus; Daniel Hunziker & Holger Kuehne et al., "DPP IV inhibitors", US patent 7803819, issued 2007-07-17

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Ramakanth_Sarabu&oldid=2662175"